LPL and hyperlipidemia: A PPARγ ligand, pioglitazone, suppressesboth hyperlipidemia and intestinal polyp formation in the APC-deficient mice inconjunction with elevation of lipoprotein lipase (LPL), which catalyzes TGhydrolysis [70].